Article
Multidisciplinary Sciences
Yunpeng Zhao, Yongqiang Wang, Lei Shan, Chuanliang Peng, Wenhao Zhang, Xiaogang Zhao
Summary: The network meta-analysis indicated that both neoadjuvant CRT and neoadjuvant CT were effective in improving the survival of patients with ESCC, with no significant difference between the two approaches. Further research is needed to support individual clinical decisions.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Hai-Bo Sun, Duo Jiang, Xian-Ben Liu, Wen-Qun Xing, Pei-Nan Chen, Shao-Kang Feng, Sen Yan
Summary: The purpose of this study was to investigate the pattern of lymph node metastases and its impact on prognosis in esophageal squamous cell carcinoma patients after neoadjuvant chemotherapy. The results showed that the most common metastasis sites were the right upper paratracheal and left gastric artery stations. Multivariable analysis revealed that ypN stage was an independent predictor of survival. Therefore, the lymph node metastasis pattern and ypN stage can provide guidance on the extent of lymphadenectomy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
A. I. Damanakis, F. Gebauer, A. Stapper, H. A. Schloesser, M. Ghadimi, T. Schmidt, L. M. Schiffmann, H. Fuchs, T. Zander, A. Quaas, C. J. Bruns, W. Schroeder
Summary: By analyzing 715 patients with oesophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) who received neoadjuvant treatment, it was found that combining histopathologic regression and nodal status can improve the prediction of survival after treatment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Satoru Matsuda, Hirofumi Kawakubo, Akihiko Okamura, Keita Takahashi, Tasuku Toihata, Ryo Takemura, Shuhei Mayanagi, Hiroya Takeuchi, Masayuki Watanabe, Yuko Kitagawa
Summary: Histological response influenced long-term outcomes of patients post-NAC esophagectomy, even within same pathologic stage groups. Current risk stratification system aids in selecting appropriate candidates for adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Cristina Piva, Luca Panier Suffat, Edoardo T. F. Petrucci, Giovanna Manuguerra, Federico Vittone, Domenico Cante, Silvia Ferrario, Marina Paolini, Lorenzo Radici, Giorgio Vellani, Maria R. La Porta
Summary: The optimal timing of surgery following neoadjuvant chemoradiotherapy for locally advanced rectal cancer remains controversial. However, waiting for a longer period (10 weeks or more) between the end of chemoradiotherapy and surgery may increase pathological response rates.
UPDATES IN SURGERY
(2022)
Review
Oncology
Jinxin Xu, Chun Yan, Zhe Li, Yunpeng Cao, Hongbing Duan, Sunkui Ke
Summary: This study aimed to summarize the efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma (ESCC). The results showed that neoadjuvant chemoimmunotherapy had a positive impact on improving the pathological response rate and resection rate, with relatively good safety.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Jinxin Xu, Chun Yan, Zhe Li, Yunpeng Cao, Hongbing Duan, Sunkui Ke
Summary: This study aimed to summarize the efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma (ESCC). The meta-analysis results showed that neoadjuvant chemoimmunotherapy is effective and safe for resectable ESCC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Ying Li, Hanshan Liu, Chao Sun, Xudong Yin, Jiandong Tong, Xizhi Zhang, Xiaolin Wang, Xin Yuan, Zhengrong Zhang, Guangyu Lu, Yixun Gu, Yongpeng Li, Tianyu Huang, Zhe Qiao, Yong Chen
Summary: This study found that in EC/GEJ patients, lower radiation doses were associated with higher survival rates compared to higher radiation doses, as well as improved treatment safety and lower distant failure rates. The use of modern radiation therapy techniques improved oncologic outcomes, and for patients receiving conventionally fractionated radiation, a total dose of 40.0 to 41.4 Gy may be optimal.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Letter
Oncology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: This study conducted a meta-analysis on the oncological outcomes of patients with cervical esophageal squamous cell carcinoma treated with chemoradiotherapy. The results showed a local-regional failure rate of 41.4% and a distant failure rate of 21.6%. The study also found that the radiotherapy dose did not significantly affect overall survival, suggesting that increasing the dose may not improve survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Satoru Matsuda, Hirofumi Kawakubo, Takayuki Tsuji, Junya Aoyama, Yuki Hirata, Ryo Takemura, Shuhei Mayanagi, Tomoyuki Irino, Kazumasa Fukuda, Rieko Nakamura, Hiroya Takeuchi, Yuko Kitagawa
Summary: Endoscopic response evaluation can predict the distribution of residual tumors after NAC, assisting in radiation field selection for subsequent definitive CRT in patients choosing to omit TTE. It can help in organ preservation for patients responding to NAC.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Akari Sonoda, Naoya Yoshida, Shinya Shiraishi, Tomo Horinouchi, Ryuma Tokunaga, Kazuto Harada, Masaaki Iwatsuki, Yohei Nagai, Yoshifumi Baba, Shiro Iwagami, Yuji Miyamoto, Hideo Baba
Summary: This study found that changes in the TLG ratio before and after neoadjuvant chemotherapy (NAC) and subsequent esophagectomy in patients with esophageal squamous cell carcinoma (ESCC) can predict both histological response and survival outcomes. The TLG ratio was associated with pathological tumor regression grade (TRG) and was identified as an independent prognostic factor for overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Xin Xiao, Yu-Shang Yang, Xiao-Xi Zeng, Qi-Xin Shang, Si-Yuan Luan, Jian-Feng Zhou, Xiao-Kun Li, Pin-Hao Fang, Yang Hu, Long-Qi Chen, Yong Yuan
Summary: This study evaluated the short-term outcomes of neoadjuvant chemoimmunotherapy (NACI) followed by oesophagectomy for locally advanced oesophageal squamous carcinoma. The results showed that NACI was associated with lower pneumonia rate and was safe and feasible for locally advanced oesophageal squamous cancer. However, the tumour regression score and pathological complete response rate were lower in the NACI group compared to the neoadjuvant chemoradiotherapy group.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Article
Cardiac & Cardiovascular Systems
Xin Xiao, Yu-Shang Yang, Xiao-Xi Zeng, Qi-Xin Shang, Si-Yuan Luan, Jian-Feng Zhou, Xiao-Kun Li, Pin-Hao Fang, Yang Hu, Long-Qi Chen, Yong Yuan
Summary: The study found that NACI was associated with a lower pneumonia rate compared to NACR and was considered safe and feasible for locally advanced esophageal squamous cancer. However, patients treated with neoadjuvant immunotherapy had lower tumor regression scores and pathological complete response rates than those treated with NACR. The short-term follow-up results were similar between the two treatment modalities.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Article
Cardiac & Cardiovascular Systems
Marianne C. Kalff, Isolde Vesseur, Wietse J. Eshuis, David J. Heineman, Freek Daams, Donald L. van der Peet, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz
Summary: This study evaluated the clinicopathologic predictors of textbook outcome in esophageal cancer surgery and found that achieving textbook outcome was associated with better overall and disease-free survival. The study highlighted the correlation between textbook outcome and long-term survival, emphasizing the importance of pursuing textbook outcome.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Akihiko Okamura, Satoru Matsuda, Shuhei Mayanagi, Jun Kanamori, Yu Imamura, Tomoyuki Irino, Hirofumi Kawakubo, Shinji Mine, Hiroya Takeuchi, Yuko Kitagawa, Masayuki Watanabe
Summary: Elevated pretherapeutic serum SCC-Ag levels are significantly associated with advanced tumor stage, poor response to NAC, and increased risk of disease recurrence.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: Definitive chemoradiotherapy is a valuable first-line treatment for cervical esophageal squamous cell carcinoma (CESCC) with favorable oncological outcomes. Further research is needed to identify survival predictors for stage-based clinical guidelines.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Swathikan Chidambaram, Nikhil M. Patel, Viknesh Sounderajah, Rita Alfieri, Luigi Bonavina, Edward Cheong, Andy Cockbain, Xavier Benoit D'Journo, Lorenzo Ferri, Ewen A. Griffiths, Peter Grimminger, Caroline Gronnier, Christian Gutschow, Jakob Hedberg, Joonas H. Kauppila, Sjoerd Lagarde, Donald Low, Philippe Nafteux, Grard Nieuwenhuijzen, Magnus Nilsson, Riccardo Rosati, Wolfgang Schroeder, B. Mark Smithers, Mark I. van Berge Henegouwen, Richard van Hillegesberg, David Watson, Ravinder Vohra, Nick Maynard, Sheraz R. Markar
Summary: Currently, there is a lack of evidence-based guidelines for surveillance of recurrence after esophageal and gastric (OG) cancer surgical resection. This study used a modified Delphi consensus process to identify eight symptoms that should prompt further investigations for suspected recurrent malignancy.
DISEASES OF THE ESOPHAGUS
(2023)
Article
Oncology
N. Schuring, E. Jezerskyte, M. I. van Berge Henegouwen, M. A. G. Sprangers, P. Lagergren, A. Johar, S. R. Markar, S. S. Gisbertz
Summary: This study aimed to investigate the relationship between postoperative complications and long-term health-related quality of life (HRQL) in patients who underwent esophagectomy for cancer. The study found that patients with complications reported more dyspnea compared to those without complications, but these differences were not clinically significant. The severity of complications also had an impact on the patients' mood. Overall, HRQL in esophageal cancer patients is more likely affected by the complexity of the surgical procedure itself.
Review
Otorhinolaryngology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: The study aims to determine the oncological outcomes of surgery for cervical esophageal cancer. The results showed different survival rates between larynx preserving surgery and non-preserving surgery, and further research is needed to compare the effects of surgery and chemoradiotherapy.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Ophthalmology
Elina S. Rantala, Raffaele Parrozzani, Micaela M. Hernberg, Vanna Chiarion-Sileni, Tero T. Kivela, Edoardo Midena
Summary: The study aims to build and validate a prognostic model for predicting long-term overall survival in metastatic choroidal and ciliary body melanoma. The study analyzed the predictors of intermediate and long-term survival in a Finnish cohort, and validated the models using an Italian cohort. The results showed that alkaline phosphatase or lactate dehydrogenase >2 times the upper normal limit essentially precluded long-term survival, and the most robust predictor was distant metastasis-free interval >42 months.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Oncology
Paolo A. A. Ascierto, Mario Mandala, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Summary: This study is a randomized, three-arm, noncomparative phase II trial that aims to explore sequential immunotherapy and BRAF/MEK inhibition for patients with BRAFV600-mutant metastatic melanoma. The results show that sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Andromachi Kotsafti, Matteo Fassan, Francesco Cavallin, Valentina Angerilli, Luca Saadeh, Matteo Cagol, Rita Alfieri, Pierluigi Pilati, Carlo Castoro, Ignazio Castagliuolo, Melania Scarpa, Marco Scarpa
Summary: This study found that immune marker expression, oncogene status, and intra- and peritumoral immune infiltrating cells are associated with lymph node metastasis in patients with esophageal adenocarcinoma. These results suggest that immune surveillance failure is the key driver of lymph node metastasis.
Article
Oncology
Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini
Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.
Article
Oncology
Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paolo. A. Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Ketty Peris, Paola Queirolo, Luisa Fioretto, Corrado Caraco, Miriam Paone, Antonio Sorrentino, Mariaelena Capone, Diana Giannarelli, Gerardo Ferrara, Daniela Massi, Claudia Trojaniello
Summary: This study aims to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma. The study is a phase II, open-label, non-comparative trial in patients with stage IIIB/C/D surgically resectable melanoma. It is expected that the combination of neoadjuvant and adjuvant treatment may reduce the incidence of relapse and improve survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Paolo A. Ascierto, Anna M. Di Giacomo, Vanna Chiarion Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandala, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier F. Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Maio, Pietro Quaglino, Michele Del Vecchio
Summary: The CheckMate 238 study demonstrated the benefits of nivolumab over ipilimumab for melanoma patients and showed a tolerable safety profile. The Italian Expanded Access Programme enrolled 611 patients with resected melanoma and showed similar clinical activity and safety of nivolumab in a real-life setting.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Maria Chiara Scaini, Luisa Piccin, Davide Bassani, Antonio Scapinello, Stefania Pellegrini, Cristina Poggiana, Cristina Catoni, Debora Tonello, Jacopo Pigozzo, Luigi Dall'Olmo, Antonio Rosato, Stefano Moro, Vanna Chiarion-Sileni, Chiara Menin
Summary: The FDA has approved MAPK inhibitors for treating melanoma patients with BRAF gene mutation in the V600 codon. However, rare BRAF mutations outside the V600 codon may also cause melanoma, and their response to BRAF inhibitor treatment is still not well understood. In this study, a patient with a rare p.T599dup B-RAF mutation was found to have a good response to Dabrafenib/Trametinib targeted therapy. In-silico modeling showed that Dabrafenib could effectively bind to this rare mutation, suggesting the possibility of broadening the spectrum of BRAF inhibitor-sensitive mutations beyond the V600 codon.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, Massimo Guidoboni, Roberta Depenni, Alessandro Minisini, Francesca Consoli, Paolo Antonio Ascierto, Gaetana Rinaldi, Maria Banzi, Riccardo Marconcini, Rossana Gueli, Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, Giovanni Lo Re, Michele Guida, Michele Del Vecchio, Ilaria Gioia Marcon, Paola Queirolo
Summary: Brain metastases and high LDH levels are associated with poor prognosis in melanoma patients. The effectiveness of dabrafenib plus trametinib in patients with brain metastases is limited.
Meeting Abstract
Oncology
Jason J. Luke, Paolo Antonio Ascierto, Muhammad Adnan Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. Eggermont, Georgina V. Long
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. De Ruvo, B. Barberio, F. Zingone, L. Bonanno, A. Dal Maso, F. Stefano, V. Chiarion Sileni, E. V. Savarino
JOURNAL OF CROHNS & COLITIS
(2023)